Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Lars Iversen
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

Sandy McBride
Royal Free London NHS Foundation Trust, London, UK

Melinda Gooderham
SkiN Centre for Dermatology, Probity Medical Research and Queen’s University, Peterborough, ON, Canada

Petra Staubach
University of Mainz, Mainz, Germany

Paul Yamauchi
Dermatology Institute and Skin Care Center, Santa Monica, CA, USA

Fabienne Staelens
UCB Pharma

Veerle Vanoorden
UCB Pharma

Katy White
UCB Pharma

Paolo Gisondi
University of Verona, Verona, Italy

Keywords

bimekizumab, efficacy, psoriasis, BE RADIANT trial

Abstract

N/A

References

1 Glatt S. Ann Rheum Dis 2017;77:523–32;

2 Reich K. N Engl J Med 2021; 385:142–52;

3 Edson-Heredia E. J Invest Dermatol 2014;134:18–23

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.53

Article Details

How to Cite
Blauvelt, A. ., Iversen, L., McBride, S. ., Gooderham, M., Staubach, P., Yamauchi, P., Staelens, F., Vanoorden, V., White, K. ., & Gisondi, P. (2021). Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. SKIN The Journal of Cutaneous Medicine, 5(6), s53. https://doi.org/10.25251/skin.5.supp.53
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Poster Presentations from FC21 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>